Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 15/20 | 0.85 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095622 | 0.85 | ADORA1 (1.00) | ADORA1ADORA2AADORA3KDM4EMAPT | |
| SCHEMBL13913708 | 0.81 | RET (0.74) | ADORA1ADORA2AKDM4EMAPTNPSR1 | |
| SCHEMBL13914414 | 0.81 | RET (0.72) | ADORA1ADORA2AKDM4ENPSR1RXFP1 | |
| SCHEMBL13913710 | 0.80 | RET (0.73) | ADORA1ADORA2AKDM4EMAPTNPSR1 | |
| SCHEMBL13914548 | 0.80 | RET (0.75) | ADORA1KDM4EMAPTNPSR1RXFP1 | |
| SCHEMBL13914431 | 0.79 | RET (0.69) | ADORA1ADORA2AKDM4ENPSR1RXFP1 | |
| SCHEMBL28427355 | 0.79 | RET (1.00) | ADORA1ADORA2AKDM4ENPSR1RXFP1 | |
| SCHEMBL13914553 | 0.78 | RET (0.71) | ADORA1ADORA2AADORA3KDM4EMAPT | |
| SCHEMBL13914609 | 0.77 | RET (0.76) | ADORA1KDM4EMAPTNPSR1RXFP1 | |
| SCHEMBL13914570 | 0.77 | RET (0.76) | ADORA1ADORA2AADORA3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569645-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1569932-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | US | claimed |
| WO-2004055015-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| WO-2004054505-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| EP-1569645-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569751-A2 | METHODS FOR PREPARING CATALYSTS | ExxonMobil Research and Engineering Company (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569932-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004055015-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054505-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| WO-2004045767-A2 | METHODS FOR PREPARING CATALYSTS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP2K2, MAP3K2 | ADORA1 3401/4885ADORA2A 1929/4885ADORA3 3605/4885 |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | MAP4K2, MAP3K20, MAPKAPK2 | ADORA1 1798/4885ADORA2A 877/4885ADORA3 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.